Macrophage Activation Syndrome

Indian Journal of Pediatrics

Volumn 83, Issue 3, 2016, Pages 248-253

  Sen, Ethan S ^a,b   Clarke, Sarah L N ^a,b   Ramanan, Athimalaipet V ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Hemophagocytic lymphohistiocytosis; Hyperferritinemia; Interleukin 1; Macrophage activation syndrome; Systemic juvenile idiopathic arthritis

Indexed keywords

CYCLOSPORIN; ETOPOSIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; CYTOKINE; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

BONE MARROW BIOPSY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; EARLY DIAGNOSIS; ERYTHROPHAGOCYTOSIS; FEVER; HEPATOSPLENOMEGALY; HUMAN; LABORATORY TEST; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; MENTAL DISEASE; REVIEW; RHEUMATIC DISEASE; DIAGNOSTIC IMAGING;

ANTIBODIES, MONOCLONAL; CYTOKINES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGE ACTIVATION SYNDROME;

EID: 84959167076     PISSN: 00195456     EISSN: 09737693     Source Type: Journal    
DOI: 10.1007/s12098-015-1877-1     Document Type: Review

References (45)

1. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40:1285–92.
2. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421–6.
3. Ramanan AV, Schneider R. Macrophage activation syndrome—what’s in a name! J Rheumatol. 2003;30:2513–6.
4. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.
5. Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr. 2011;63:459–66.
6. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71.
7. Parodi A, Davì S, Pringe AB, et al; Lupus Working Group of the Paedtric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388–99.
8. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148:683–6.
9. Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol. 2010;32:527–31.
10. Simonini G, Pagnini I, Innocenti L, Calabri GB, De Martino M, Cimaz R. Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer. 2010;55:592.
11. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750–4.
12. Davies SV, Dean JD, Wardrop CA, Jones JH. Epstein-Barr virus-associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol. 1994;33:495–7.
13. Sterba G, Rodriguez C, Sifontes S, Vigilanza P. Macrophage activation syndrome due to methotrexate in a 12-y-old boy with dermatomyositis. J Rheumatol. 2004;31:1014–5. author reply 5.
14. Lin CI, Yu HH, Lee JH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31:1223–30.
15. Heaton DC, Moller PW. Still’s disease associated with Coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis. 1985;44:341–4.
16. Raju S, Kalyanaraman S, Swaminathan K, Nisha A, Praisid S. Hemophagocytic lymphohistiocytosis syndrome in Dengue hemorrhagic fever. Indian J Pediatr. 2014;81:1381–3.
17. van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome. Front Med (Lausanne). 2015;2:4.
18. Rajagopala S, Singh N. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent. Acta Med Acad. 2012;41:161–74.
19. Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:865–7.
20. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401–3.
21. Grom A, Ramanan A. Macrophage activation syndrome. In: Watts R, Conaghan P, Denton C, Foster H, Isaacs J, Müller-Ladner U, editors. Oxford textbook of rheumatology. 4th ed. New York: Oxford University Press; 2013. p. 1442–6.
22. Ramanan AV, Rosenblum ND, Feldman BM, Laxer RM, Schneider R. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2068–70.
23. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120–4.
24. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:1227–35.
25. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.
26. Davì S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:2871–80.
27. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604.
28. Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8.
29. Minoia F, Davi S, Bovis F, et al. Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol. 2014;12:O1.
30. Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheum. 2014;66:3160–9.
31. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277–92.
32. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128:275–8.
33. Tristano AG, Casanova-Escalona L, Torres A, Rodríguez MA. Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol. 2003;9:253–8.
34. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–98.
35. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol. 2009;132:10–8.
36. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615–20.
37. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011;50:417–9.
38. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55.
39. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol. 2009;15:161–4.
40. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.
41. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.
42. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.
43. Savage E, Wazir T, Drake M, Cuthbert R, Wright G. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology. 2014;53:1352–3.
44. Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–94.
45. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007;29:569–73.